Skip to main content

Advertisement

Table 1 Clinical and Pathologic Features of Study Patients

From: The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence

   CCIH   CCF   RPCI
   Total Her2+ Total Her2+ Her2+
ER N 452 69 240 81 64
  + 311 38 186 59 32
  - 135 31 42 20 28
  n/a 6 0 12 2 4
PR + 234 20 128 30 10
  - 204 48 104 48 46
  n/a 14 1 8 3 8
Age Mean 58 56 62 61 56
  <50 132 25 57 25 23
  > = 50 320 44 183 56 41
Nodal Stage 0 259 34 135 52 23
  1 176 32 56 16 31
  2 8 3 24 10 5
  3 0 0 8 2 3
  n/a 9 0 17 1 2
Tumor Stage 1 234 26 133 42 29
  2 168 35 83 29 22
  3 21 2 12 4 5
  4 12 4 10 5 5
  n/a 17 2 2 1 3
Clinical Stage 1 172 19 90 31 15
  2A 133 19 62 27 23
  2B 92 21 26 7 11
  3A 15 1 27 9 7
  3B 16 7 8 4 3
  3C 0 0 8 2 3
  n/a 24 2 19 1 2
Grade 1 69 5 31 7 4
  2 175 21 101 35 22
  3 162 32 72 34 35
  n/a 90 11 36 5 3
Chemo None 250 28 115 31 18
  Adjuvant 241 41 74 22 45
  n/a 5 0 51 28 1